Home
Mohn Cancer Research Laboratory

Clinical studies

At Mohn Cancer Research Laboratory we analyze data from newly completed clinical trials. In addition, we participate in several ongoing trials that are actively recruiting patients.

Main content

Ongoing clinical studies:

Breast cancer and p53 mutations: Chemotherapy with cyclophosphamide

The p53 breast-study is a clinical trial where patients with breast cancer are given a specific chemotherapeutic drug called cyclophosphamide. We study whether mutations in the TP53 gene or other important genes in the tumour are crucial to response to the therapy or not. 

The study is a collaboration between the cancer departments at Haukeland University Hospital (HUS, Bergen) (leads the study) and at the University Hospital of North Norway (UNN, Tromsø), St. Olavs Hospital (Trondheim), Stavanger universitetssykehus (SUS) and Akershus universitetssykehus (Ahus, Lørenskog).

Sequential chemotherapy prior to surgery in localized soft tissue sarcoma 

The goal of this study is to evaluate the effect and safety of sequential treatment with iphosphamide and doxorubicine prior to surgery in patients with soft tissue sarcoma without metastases and a with a high risk of relapse.

This study is a collaboration between Oslo University Hospital (OUS) and Haukeland University Hospital (HUS, Bergen).

IMPRESS Norway: Implementation of personalized medicine in Norway

Personalized cancer treatment means that we use the characteristics of the cancer cells/tumours in individual patients to treat as precisely as possible. In this way, we aim to achieve an efficient treatment with few side effects.

This study is a national collaboration study lead by Oslo University Hospital (OUS).

 

Completed clinical studies:

Breast cancer PETREMAC: Personalized treatment

The PETREMAC-trial is a study of personalized treatment for patients with locally advanced breast cancer. The aim of the study is to identify mutations in the tumour that can predict resistance or sensitivity to specific therapies in individual patients.

The study was led by Haukeland University Hospital in Bergen and was a collaboration with the cancer departments at University Hospital of North Norway (UNN, Tromsø), St. Olavs Hospital (Trondheim), Helse Førde, Helse Fonna (Haugesund)Stavanger universitetssykehus (SUS) and Akershus universitetssykehus (Ahus, Lørenskog).

The study ended patient recruitment in 2020.

Colorectal cancer: Chemotherapy with cyclophosphamide for patients with metastases from colorectal cancer and TP53 mutations

In this trial we aim to assess whether patients with metastases from colorectal cancer and mutations in the TP53 gene may have an effect from treatment with the chemotherapeutic drug cyclophosphamide.

The study was carried out at Haukeland University Hospital in Bergen. 

The study ended patient recruitment in 2020.

Predictors for response to dose-dense epirubicin and docetaxel breast cancer (DDP) 

The scientific aim of this study was to explore mechanisms of resistance to chemotherapy in breast cancer. To do so, we recorded molecular parameters in patients with large primary breast cancer who received treatment with dose-dense epirubicin followed by docetaxel, prior to surgery.

The study was carried out at Haukeland University Hospital in Bergen. 

The study completed patient recruitment in 2016.
 

Evaluation of epirubicin versus paclitaxel for primary medical treatment (EPITAX)

In this study we aimed to evaluate and compare the clinical effects of optimal doses of epi-rubicin versus paclitaxel monotherapy, and to explore molecular mechanisms of resistance towards the two regimens in patients with locally advanced breast cancer.

The study was led by Haukeland University Hospital in Bergen and was a collaboration with the cancer departments at University Hospital of North Norway (UNN, Tromsø), St. Olavs Hospital (Trondheim), Stavanger universitetssykehus (SUS), Oslo universitetssykehus Ullevål (US, Ullevål) and Oslo universitetssykehus Radiumhospitalet (RH, Oslo).

The study completed patient recruitment in 2003.